Search

Your search keyword '"Palmieri, Raffaele"' showing total 22 results

Search Constraints

Start Over You searched for: Author "Palmieri, Raffaele" Remove constraint Author: "Palmieri, Raffaele" Database ScienceDirect Remove constraint Database: ScienceDirect
22 results on '"Palmieri, Raffaele"'

Search Results

1. Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia

2. The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia

3. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol

5. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

6. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms

7. Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

8. Optimal Prognostic Threshold for Acute Myeloid Leukemia (AML) Measurable Residual Disease (MRD) Positivity By Multiparameter Flow Cytometry: A Report of 2,051 Patients from MRC/NCRI, Gimema, HOVON, and Seattle

9. Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

10. Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

11. Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

12. Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

13. Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

17. Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)

18. Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients

19. Second Generation Tyrosine Kinase Inhibitors (2G-TKI) in the Frontline Treatment of Elderly Patients with Chronic Myeloid Leukemia

21. Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT)

22. Initial Therapeutic Approach and Relationship with Clinical and Biological Characteristics at Diagnosis in 2418 Patients of the Registro Italiano Trombocitemie (RIT)

Catalog

Books, media, physical & digital resources